Product news

Share this article:

An FDA advisory panel voted that a long-acting, injectable form of Eli Lilly's best-selling drug, the antipsychotic olanzapine, is safe enough for use in some patients with schizophrenia. But panel members shared concerns raised by the FDA that Zyprexa LAI was associated with excessive sedation.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.